{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T14:25:30Z","timestamp":1787063130055,"version":"build-2736575974"},"reference-count":27,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T00:00:00Z","timestamp":1783036800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Drug Investig"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40261-026-01578-4","type":"journal-article","created":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T08:46:57Z","timestamp":1783068417000},"page":"985-994","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Assessing the Adverse Events of Roflumilast and Tapinarof Use in Pediatric and Young Adult Patients with Atopic Dermatitis: A Systematic Review"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0009-0001-0453-8807","authenticated-orcid":false,"given":"Anya","family":"Ramsamooj","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany M.","family":"Joy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"suffix":"Jr.","given":"Dave D.","family":"Manguerra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valerie A.","family":"Gerriets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,3]]},"reference":[{"key":"1578_CR1","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1093\/bjd\/ljad339","volume":"190","author":"J Tian","year":"2023","unstructured":"Tian J, Zhang D, Yang Y, Huang Y, Wang L, Yao X, et al. Global epidemiology of atopic dermatitis: a comprehensive systematic analysis and modelling study. Br J Dermatol. 2023;190:55\u201361. https:\/\/doi.org\/10.1093\/bjd\/ljad339.","journal-title":"Br J Dermatol"},{"key":"1578_CR2","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/S0140-6736(24)02519-4","volume":"405","author":"E Guttman-Yassky","year":"2025","unstructured":"Guttman-Yassky E, Renert-Yuval Y, Brunner PM. Atopic dermatitis. Lancet. 2025;405:583\u201396. https:\/\/doi.org\/10.1016\/S0140-6736(24)02519-4.","journal-title":"Lancet"},{"key":"1578_CR3","doi-asserted-by":"publisher","DOI":"10.3390\/children8111067","volume":"8","author":"M Tsuge","year":"2021","unstructured":"Tsuge M, Ikeda M, Matsumoto N, Yorifuji T, Tsukahara H. Current insights into atopic march. Children. 2021;8:1067. https:\/\/doi.org\/10.3390\/children8111067.","journal-title":"Children"},{"key":"1578_CR4","doi-asserted-by":"publisher","first-page":"S118","DOI":"10.1016\/j.jaci.2003.09.033","volume":"112","author":"JM Spergel","year":"2003","unstructured":"Spergel JM, Paller AS. Atopic dermatitis and the atopic march. J Allergy Clin Immunol. 2003;112:S118\u201327. https:\/\/doi.org\/10.1016\/j.jaci.2003.09.033.","journal-title":"J Allergy Clin Immunol"},{"key":"1578_CR5","doi-asserted-by":"publisher","first-page":"84","DOI":"10.2500\/aap.2019.40.4202","volume":"40","author":"J Kim","year":"2019","unstructured":"Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: clinical implications. Allergy Asthma Proc. 2019;40:84\u201392. https:\/\/doi.org\/10.2500\/aap.2019.40.4202.","journal-title":"Allergy Asthma Proc"},{"key":"1578_CR6","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1016\/j.jaci.2023.08.030","volume":"152","author":"DK Chu","year":"2023","unstructured":"Chu DK, Chu AWL, Rayner DG, Guyatt GH, Yepes-Nu\u00f1ez JJ, Gomez-Escobar L, et al. Topical treatments for atopic dermatitis (eczema): systematic review and network meta-analysis of randomized trials. J Allergy Clin Immunol. 2023;152:1493\u2013519. https:\/\/doi.org\/10.1016\/j.jaci.2023.08.030.","journal-title":"J Allergy Clin Immunol"},{"key":"1578_CR7","doi-asserted-by":"publisher","unstructured":"Cury Martins J, Martins C, Aoki V, Gois AFT, Ishii HA, da Silva EMK. Topical tacrolimus for atopic dermatitis. Cochrane Database Syst Rev. 2015;2015:CD009864. https:\/\/doi.org\/10.1002\/14651858.CD009864.pub2","DOI":"10.1002\/14651858.CD009864.pub2"},{"key":"1578_CR8","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1016\/j.anai.2022.03.004","volume":"128","author":"S Butala","year":"2022","unstructured":"Butala S, Paller AS. Optimizing topical management of atopic dermatitis. Ann Allergy Asthma Immunol. 2022;128:488\u2013504. https:\/\/doi.org\/10.1016\/j.anai.2022.03.004.","journal-title":"Ann Allergy Asthma Immunol"},{"key":"1578_CR9","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2025-071812","volume":"155","author":"JJ Schoch","year":"2025","unstructured":"Schoch JJ, Anderson KR, Jones AE, Tollefson MM, Section on Dermatology, Wright T, et al. Atopic dermatitis: update on skin-directed management: clinical report. Pediatrics. 2025;155:e2025071812. https:\/\/doi.org\/10.1542\/peds.2025-071812.","journal-title":"Pediatrics"},{"key":"1578_CR10","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1016\/j.jaad.2024.05.023","volume":"91","author":"JI Silverberg","year":"2024","unstructured":"Silverberg JI, Eichenfield LF, Hebert AA, Simpson EL, Stein Gold L, Bissonnette R, et al. Tapinarof cream 1% once daily: significant efficacy in the treatment of moderate to severe atopic dermatitis in adults and children down to 2 years of age in the pivotal phase 3 ADORING trials. J Am Acad Dermatol. 2024;91:457\u201365. https:\/\/doi.org\/10.1016\/j.jaad.2024.05.023.","journal-title":"J Am Acad Dermatol"},{"key":"1578_CR11","doi-asserted-by":"publisher","unstructured":"Simpson EL, Eichenfield LF, Alonso-Llamazares J, Draelos ZD, Ferris LK, Forman SB, et al. Roflumilast cream, 0.15%, for atopic dermatitis in adults and children: INTEGUMENT-1 and INTEGUMENT-2 randomized clinical trials. JAMA Dermatol. 2024;160:1161. https:\/\/doi.org\/10.1001\/jamadermatol.2024.3121","DOI":"10.1001\/jamadermatol.2024.3121"},{"key":"1578_CR12","doi-asserted-by":"publisher","first-page":"745.e1","DOI":"10.1016\/j.jaad.2025.05.1386","volume":"93","author":"DMR Davis","year":"2025","unstructured":"Davis DMR, Frazer-Green L, Alikhan A, Bercovitch L, Cohen DE, Darr JM, et al. Focused update: guidelines of care for the management of atopic dermatitis in adults. J Am Acad Dermatol. 2025;93:745.e1-745.e7. https:\/\/doi.org\/10.1016\/j.jaad.2025.05.1386.","journal-title":"J Am Acad Dermatol"},{"key":"1578_CR13","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n71","author":"MJ Page","year":"2020","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2020. https:\/\/doi.org\/10.1136\/bmj.n71.","journal-title":"BMJ"},{"key":"1578_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1111\/pde.15840","volume":"42","author":"LF Eichenfield","year":"2025","unstructured":"Eichenfield LF, Serrao R, Prajapati VH, Browning JC, Swanson L, Funk T, et al. Efficacy and safety of once\u2010daily roflumilast cream 0.05% in pediatric patients aged 2\u20135 years with mild\u2010to\u2010moderate atopic dermatitis (INTEGUMENT\u2010PED): a phase 3 randomized controlled trial. Pediatr Dermatol. 2025;42:296\u2013304. https:\/\/doi.org\/10.1111\/pde.15840.","journal-title":"Pediatr Dermatol"},{"key":"1578_CR15","doi-asserted-by":"publisher","DOI":"10.1080\/09546634.2024.2444489","volume":"36","author":"LS Gold","year":"2025","unstructured":"Gold LS, Del Rosso J, Ehst BD, Zirwas MJ, Green LJ, Brown PM, et al. Tapinarof cream 1% once daily was well tolerated in adults and children with atopic dermatitis in two phase 3 randomized trials. J Dermatolog Treat. 2025;36:2444489. https:\/\/doi.org\/10.1080\/09546634.2024.2444489.","journal-title":"J Dermatolog Treat"},{"key":"1578_CR16","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/1346-8138.17587","volume":"52","author":"A Igarashi","year":"2025","unstructured":"Igarashi A, Tsuji G, Murata R, Fukasawa S, Yamane S. A phase 2, randomized, double\u2010blind, vehicle\u2010controlled trial of tapinarof cream in Japanese pediatric patients with atopic dermatitis. J Dermatol. 2025;52:247\u201355. https:\/\/doi.org\/10.1111\/1346-8138.17587.","journal-title":"J Dermatol"},{"key":"1578_CR17","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s40257-025-00929-9","volume":"26","author":"AS Paller","year":"2025","unstructured":"Paller AS, Hebert AA, Gonzalez ME, Butners V, Fitzgerald N, Tabolt G, et al. Maximal usage trial of tapinarof cream 1% once daily in pediatric patients down to 2 years of age with extensive atopic dermatitis. Am J Clin Dermatol. 2025;26:449\u201356. https:\/\/doi.org\/10.1007\/s40257-025-00929-9.","journal-title":"Am J Clin Dermatol"},{"key":"1578_CR18","doi-asserted-by":"publisher","DOI":"10.1089\/derm.2024.0418","author":"EL Simpson","year":"2025","unstructured":"Simpson EL, Eichenfield LF, Papp KA, Forman SB, Hebert AA, Gonzalez ME, et al. Long-term safety and efficacy with roflumilast cream 0.15% in patients aged \u22656 years with atopic dermatitis: a phase 3 open-label extension trial. Dermatitis. 2025. https:\/\/doi.org\/10.1089\/derm.2024.0418.","journal-title":"Dermatitis"},{"key":"1578_CR19","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.pedn.2019.03.018","volume":"47","author":"AB Fishbein","year":"2019","unstructured":"Fishbein AB, Mueller K, Lor J, Smith P, Paller AS, Kaat A. Systematic review and meta-analysis comparing topical corticosteroids with vehicle\/moisturizer in childhood atopic dermatitis. J Pediatr Nurs. 2019;47:36\u201343. https:\/\/doi.org\/10.1016\/j.pedn.2019.03.018.","journal-title":"J Pediatr Nurs"},{"key":"1578_CR20","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2020-046476","volume":"11","author":"E Axon","year":"2021","unstructured":"Axon E, Chalmers JR, Santer M, Ridd MJ, Lawton S, Langan SM, et al. Safety of topical corticosteroids in atopic eczema: an umbrella review. BMJ Open. 2021;11:e046476. https:\/\/doi.org\/10.1136\/bmjopen-2020-046476.","journal-title":"BMJ Open"},{"key":"1578_CR21","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1016\/j.jid.2017.05.004","volume":"137","author":"SH Smith","year":"2017","unstructured":"Smith SH, Jayawickreme C, Rickard DJ, Nicodeme E, Bui T, Simmons C, et al. Tapinarof is a natural AhR agonist that resolves skin inflammation in mice and humans. J Invest Dermatol. 2017;137:2110\u20139. https:\/\/doi.org\/10.1016\/j.jid.2017.05.004.","journal-title":"J Invest Dermatol"},{"key":"1578_CR22","doi-asserted-by":"publisher","DOI":"10.3390\/ijms20215424","volume":"20","author":"M Furue","year":"2019","unstructured":"Furue M, Hashimoto-Hachiya A, Tsuji G. Aryl hydrocarbon receptor in atopic dermatitis and psoriasis. Int J Mol Sci. 2019;20:5424. https:\/\/doi.org\/10.3390\/ijms20215424.","journal-title":"Int J Mol Sci"},{"key":"1578_CR23","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.3389\/fphar.2018.01048","volume":"9","author":"H Li","year":"2018","unstructured":"Li H, Zuo J, Tang W. Phosphodiesterase-4 inhibitors for the treatment of inflammatory Diseases. Front Pharmacol. 2018;9:1048. https:\/\/doi.org\/10.3389\/fphar.2018.01048.","journal-title":"Front Pharmacol"},{"key":"1578_CR24","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/j.jdrv.2025.07.004","volume":"6","author":"ME Sowa","year":"2025","unstructured":"Sowa ME, Grewal PS. Off-label therapeutic potential of topical roflumilast in dermatology: a narrative review. JAAD Rev. 2025;6:27\u201332. https:\/\/doi.org\/10.1016\/j.jdrv.2025.07.004.","journal-title":"JAAD Rev"},{"key":"1578_CR25","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1007\/s40257-022-00741-9","volume":"24","author":"AW Thurston","year":"2023","unstructured":"Thurston AW, Osborne DW, Snyder S, Higham RC, Burnett P, Berk DR. Pharmacokinetics of roflumilast cream in chronic plaque psoriasis: data from phase I to phase III studies. Am J Clin Dermatol. 2023;24:315\u201324. https:\/\/doi.org\/10.1007\/s40257-022-00741-9.","journal-title":"Am J Clin Dermatol"},{"key":"1578_CR26","unstructured":"Arcutis Biotherapeutics. FDA Approves Arcutis\u2019 ZORYVE\u00ae (roflumilast) Cream 0.15% for the Treatment of Atopic Dermatitis in Adults and Children Down to 6 Years of Age [Internet]. Arcutis Biotherapeutics; 2024 [cited 2025 Sept 19]. http:\/\/arcutis.com\/fda-approves-arcutis-zoryve-roflumilast-cream-0-15-for-the-treatment-of-atopic-dermatitis-in-adults-and-children-down-to-6-years-of-age\/. Accessed 19 Sept 2025"},{"key":"1578_CR27","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s40272-025-00689-3","volume":"27","author":"SM Hoy","year":"2025","unstructured":"Hoy SM. Tapinarof cream 1%: pediatric first approval. Pediatr Drugs. 2025;27:383\u201391. https:\/\/doi.org\/10.1007\/s40272-025-00689-3.","journal-title":"Pediatr Drugs"}],"container-title":["Clinical Drug Investigation"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01578-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40261-026-01578-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40261-026-01578-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T13:32:47Z","timestamp":1787059967000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40261-026-01578-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,3]]},"references-count":27,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1578"],"URL":"https:\/\/doi.org\/10.1007\/s40261-026-01578-4","relation":{},"ISSN":["1173-2563","1179-1918"],"issn-type":[{"value":"1173-2563","type":"print"},{"value":"1179-1918","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,3]]},"assertion":[{"value":"15 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors have no competing interests to declare that are relevant to the content of this article.","order":1,"name":"Ethics","label":"Conflict of interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":4,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":5,"name":"Ethics","label":"Code availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All data generated or analyzed during this study are included in this published article (and its supplementary information files).","order":6,"name":"Ethics","label":"Availability of data material","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anya Ramsamooj: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Validation, Visualization, Writing\u2014original draft, Writing\u2014reviewing and editing; Bethany Joy: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Validation, Visualization, Writing\u2014original draft, Writing\u2014reviewing and editing; Dave Manguerra Jr: Conceptualization, Data Curation, Investigation, Methodology, Validation, Writing\u2014original draft, Writing\u2014reviewing and editing; Valerie Gerriets: Conceptualization, Methodology, Project Administration, Supervision, Validation, Writing\u2014original draft, Writing\u2014reviewing and editing. All authors read and approved the final version of this manuscript and agree to be accountable for the work.","order":7,"name":"Ethics","label":"Author\u2019s contributions","group":{"name":"EthicsHeading","label":"Declarations"}}]}}